Combination Trans Arterial Chemoembolization (TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review of the Literature

[1]  D. Fan,et al.  Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Y. Chao,et al.  Interim analysis of START: Study in asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial , 2013, International journal of cancer.

[3]  G. Han,et al.  Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: A propensity score matching study , 2013, Journal of digestive diseases.

[4]  L. Johnson,et al.  Transplantation for hepatocellular carcinoma in younger patients has an equivocal survival advantage as compared with resection. , 2013, Transplantation proceedings.

[5]  Joong-Won Park,et al.  Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. , 2012, Journal of hepatology.

[6]  V. Conteduca,et al.  Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. , 2012, The oncologist.

[7]  A. Zekri,et al.  Hepatitis C virus and other risk factors in hepatocellular carcinoma. , 2012, Acta virologica.

[8]  Jian-hua Wang,et al.  The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma , 2012, BMC Cancer.

[9]  A. Ba-Ssalamah,et al.  Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study , 2012, European Radiology.

[10]  T. Pawlik,et al.  Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Kudo,et al.  Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. , 2011, European journal of cancer.

[12]  T. George,et al.  The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma , 2011, Alimentary pharmacology & therapeutics.

[13]  V. Mazzaferro,et al.  Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. , 2011, Cancer treatment reviews.

[14]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[15]  J. Dufour,et al.  Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. , 2010, The oncologist.

[16]  Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire.  A Comparison of Lipiodol Chemoembolization and Conservative Treatment for Unresectable Hepatocellular Carcinoma , 2009 .

[17]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[18]  R. Epstein,et al.  Evolution of systemic therapy of advanced hepatocellular carcinoma. , 2008, World journal of gastroenterology.

[19]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[20]  C. Zheng,et al.  Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. , 2004, World journal of gastroenterology.

[21]  J. Bruix,et al.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.

[22]  M. Sherman,et al.  Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto , 2002, Gut.

[23]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[24]  J. Pignon,et al.  Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. , 1998, Journal of hepatology.

[25]  J. Bruix,et al.  Treatment of hepatocellular carcinoma. , 2006, Critical reviews in oncology/hematology.

[26]  H. Hasegawa,et al.  Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients , 1985, Cancer.